原血栓性PROC变异重新平衡严重血友病A患者的血静,降低出血风险
Radha Ramanan1, Quentin Van Thillo2, Renaud Lavend'homme3
1Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium; Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia; Ronald Sawers Haemophilia Treatment Centre, Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia; Department of Human Molecular Pathology, Alfred Hospital, Melbourne, Victoria, Australia.
一名患有严重血友病A (HA) 的患者由于基因修饰剂而出现轻度出血表型. 一种蛋白C (PC) 变体部分降低了PC水平,改善了血栓生成,并减轻了HA中的出血严重程度.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
背景情况:
- 严重的血友病A (HA) 的特点是因子VIII (FVIII) 水平<1%和显著的出血风险.
- 一名患有严重F8变异的患者表现出比预期的更轻微的出血表型.
研究的目的:
- 确定影响严重HA患者出血严重性的遗传修饰剂.
- 研究一种新型蛋白C (PC) 变异对血液静止的功能影响.
主要方法:
- 多基因测序用于识别基因修饰剂.
- 测量血蛋白C (PC) 活性和抗原水平.
- 功能测试包括血栓生成测试 (TGA) 和重组蛋白表达.
主要成果:
- 鉴定了一种异性致病性PROC变体 (p.Trp414Arg),导致部分定量PC缺陷 (正常的53-59%).
- 与野生类型的PC相比,突变PC的活性和数量显著降低.
- 血生成试验表明,在缺乏FVIII的血中与降低PC的血中,血生成有所改善,特别是在添加血.
结论:
- 鉴定的PROC变异部分降低了PC水平,作为一种基因修饰剂,减轻了严重HA的出血严重程度.
- 这种部分缺陷在缺乏功能FVIII的情况下改善了血栓生成,重新平衡了血液静止.
- 多基因面板测序在识别复杂出血障碍的遗传修饰者方面是有效的.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...


